Bacille Calmette-Guérin (BCG) revaccination didn't help prevent sustained Mycobacterium tuberculosis infection in initially uninfected adolescents without HIV in a randomized trial from South Africa.

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application for Anktiva in patients with BCG-unresponsive non-muscle invasive bladder ...

The complete response (CR) rate to the combination of the interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln (Anktiva®) and bacillus Calmette-Guerin (BCG) in BCG-unresponsive ...

Cretostimogene for CIS-containing BCG unresponsive nonmuscle-invasive bladder cancer showed “best in class durability and tolerability,” according to investigators. Cretostimogene ...

ANKTIVA was approved by the FDA in 2024 with BCG for the treatment of BCG unresponsive NMIBC with Papillary tumors with CIS (Cohort A). In the same clinical trial (QUILT-3.032) long term results ...

With the WAVES 2025 setting a new trend in the economic and entertainment Capital of the country, two reputed international agency - BCG and E&Y - have reported that India’s creator economy is ...

Motivated to clear the misconception of climate projects being complex and nascent, lead author Daniel Oehling, a managing director and partner at BCG’s Singapore office, said the report laid out the ...

This guide walks you through a simple, actionable plan—plus includes a free template to help you stay organized and put your new strategy into motion. Download your free plan below and read ...

What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer.